Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

scarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the plans for discussing a Phase III program for tezampanel with the FDA, anticipated timing for initiating a Phase II clinical trial of tezampanel for treatment of muscle spasticity and rigidity, the anticipated timing for completing the Phase I maximum tolerated dose trial for NGS426, the potential for tezampanel and NGX426 as treatments for migraine and other indications, and the range of net cash burn targeted by management in 2008. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarant
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Scientists have developed what they believe is the ... made in sheets only three atoms thick. , ... two of these single-layer semiconductor materials can be ... a heterojunction. This result could be the basis ... diodes, or LEDs, and solar technologies. , "Heterojunctions ...
(Date:8/26/2014)... Diego, CA, and Bellingham, WA (PRWEB) August 26, ... and optical engineering, visions for next-generation wearable technology, ... 2015 among numerous highlights at this year’s brighter, ... the San Diego, California, Convention Center. More than ... last week attended conferences, courses, an exhibition, and ...
(Date:8/26/2014)... August 26, 2014 The 20 ambassadors ... ALS (YFALS) community issued the following statement on Facebook ... awareness and driving new funding specifically for ALS research: ... water and some ice would raise all this awareness ... our families, and on behalf of the entire ALS ...
(Date:8/26/2014)... been added to the growing case for graphene ... big thing in the high-tech world by the ... collaboration of researchers led by a scientist with ... National Laboratory (Berkeley Lab) has reported the first ... MX2 materials. The recorded charge transfer time clocked ...
Breaking Biology Technology:Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4Competition for graphene 2
... Dec. 13, 2011  GenVec, Inc. (Nasdaq: GNVC ... create superior therapeutics and vaccines, today announced that Paul ... his plan to retire as President and Chief Executive ... a successor is named and the CEO transition is ...
... Tarsa Therapeutics today confirmed that it is planning ... Food and Drug Administration (FDA) in the second half ... calcitonin tablet for the treatment of postmenopausal osteoporosis. This follows ... the results from Tarsa,s Phase III ORACAL trial and ...
... - The Pharmabiotic Research Institute (PRI) brings ... probiotics research. It is a unique scientific and regulatory ... that, beyond their traditional food processing applications, probiotics can ... potential. This is why PRI uses the terminology "Pharmabiotics", ...
Cached Biology Technology:GenVec President and Chief Executive Officer Announces Retirement 2GenVec President and Chief Executive Officer Announces Retirement 3Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 3The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 2The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 3The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 4
(Date:8/27/2014)... into doubt the long-standing belief that a deficiency in ... plays a central role in depression. In the journal ... lacking the ability to make serotonin in their brains ... did not show depression-like symptoms. , Donald Kuhn ... Center and Wayne State University School of Medicine note ...
(Date:8/27/2014)... to be associated with outcomes after the repair ... the patient, mechanism of injury, nerve injured, injury ... technique, and repair materials. However, despite numerous studies ... injuries, there is no agreement regarding the independent ... relationship of the predictors has not been quantified. ...
(Date:8/27/2014)... North Carolina State University have found that century-old museum specimens ... common insect pest that can weaken and kill trees ... that scale insect populations increase on oak and maple trees ... pests may also increase with global warming," says Dr. Elsa ... of a paper on the work. , "More scale insects ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Museum specimens, modern cities show how an insect pest will respond to climate change 2
... human brain is not completed at birth. There is ... place in the human brain throughout life, probably for ... that brain structure is under considerable genetic influence [Peper ... into adulthood, involves changes in brain morphology that may ...
... , Mammography continues to be the method of ... because this technique is not as selective or specific ... results for every level of tissue density, alternatives are ... of near-infrared (NIR) light instead of X-rays, is a ...
... MANHATTAN, KAN. -- An award-winning Kansas State University chemistry ... recognizing him for work on microfluidic devices. Chris ... Masao Horiba Award for "Rapid Analysis of Individual T-Lymphocyte ... Wednesday, Oct. 17, during a special ceremony at Kyoto ...
Cached Biology News:Genetic contributions to human brain morphology and intelligence 2Genetic contributions to human brain morphology and intelligence 3Genetic contributions to human brain morphology and intelligence 4Genetic contributions to human brain morphology and intelligence 5Contrast agent trials in swine 2K-State chemistry professor to receive Masao Horiba award 2
... Mount is formulated for covering tissue sections and cell preparations ... end products. , ... Application: ... or AEC that require an aqueous mounting medium, or those ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... Solution, pH 9 (x 10) This ... intended for heat-induced target retrieval prior to ... use on formalin-fixed, paraffin-embedded tissue sections mounted ... citrate buffer, pH 6, the use of ...
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
Biology Products: